Fighting COVID19 with calpain inhibitors / Consortium: Calpain-antivirals
- Funded by Academy of Finland
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$491,216.3Funder
Academy of FinlandPrincipal Investigator
Varpu MarjomäkiResearch Location
FinlandLead Research Institution
University of JyväskyläResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
It is important to develop coronavirus (CoV) targeting antivirals as it remains unclear if and when a safe and efficient vaccine becomes available. We propose to create antivirals against CoV proteases that process the virus polyprotein to virus capsid proteins by using a novel approach, by inhibiting cellular calpain enzymes. We have preliminary results showing that calpain inhibitors prevent COVID19 infection. In addition, we have shown that calpain inhibitors knock down both host cell calpains and the enteroviral protease, that both contribute to virus polyprotein processing. We reckon that calpain inhibitors attack both host cell calpain proteases and viral 3C-like protease, closely resembling enterovirus 3C protease, and both process the viral polyprotein. In the project we will find the inhibitor with best efficacy, chemically optimize the inhibitor with new design, synthesis and efficacy against virus infection.